Study of KRN951 in Patients With Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00970411|
Recruitment Status : Completed
First Posted : September 2, 2009
Last Update Posted : January 5, 2017
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumors||Drug: KRN951||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Non-randomised Dose Escalation Study of KRN951 Administered Orally to Patients With Solid Tumors|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||April 2016|
Orally once daily administration
- To define the maximum tolerated dose (MTD) of KRN-951 when administered orally for 21 days followed by a 7-day rest period.
- To evaluate the safety profile and the tolerability of KRN951 throughout the study period by assessing adverse events and laboratory values recorded during treatment.
- To determine the pharmacokinetics of KRN951 in serum
- To describe biological and clinical anti-tumor activity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00970411